Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus (PREP-COVID)
Randomized Multicenter Study Evaluating the Efficacy of Azithromycin and Hydroxychloroquine in the Prevention of SARS-CoV-2 Infection in the Hospital Population Exposed to Virus
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Bobigny, France, 93000
- Hopial Avicenne
-
Le Kremlin-Bicêtre, France, 92100
- Hôpital GHU Paris Saclay
-
Paris, France, 75015
- Hôpital Europeén Georges Pompidou
-
Paris, France, 75012
- Hopital Saint Antoine
-
Paris, France, 75014
- Hôpital Cochin
-
Paris, France, 75013
- Hôpital Broca
-
Paris, France, 75013
- Hôpital La Pitié-Salpêtrière
-
Paris, France, 75015
- Hopital Necker
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Hospital workers working at AP-HP hospitals over the age of 18
- Hospital workers who have signed consent
- No signs of COVID-19 infection
- Women who are likely to procreate should have a negative pregnancy test on inclusion day. In addition, they should use at least one effective contraceptive method before starting treatment, during treatment and up to 8 months after the last drug tested during the trial. Sexually active men should also have effective contraception during treatment and for at least 8 months after the last drug tested during the trial.
- Affiliated or beneficiary of Social Security
Exclusion Criteria:
- History of SARS-CoV-2 infection confirmed by PCR or serology is available at inclusion
- A history of clinical episode suspecting a PCR-confirmed or unconfirmed COVID-19 infection.
- Pregnancy and breastfeeding
- Allergy or contraindications to one of the 2 drugs in the study
- Known retinopathy
- Long congenital QT syndrome (or known in the family)
- QTc or 450 ms in men, or 460 ms in women, if Fc 55/mn (except in case of intense sport practice), if ESV on baseline ECG, if QRS - or 120 ms, if AC/FA, if the PR or BAV lengthening
- History of severe ischemic heart disease or unbalanced heart failure.
- Clinically significant bradycardia known
- Known kidney or liver failure
- Known G6PD deficit
- Subject who received antiviral treatment in the 14 days prior to inclusion
- Subject who had treatment with azithromycin or hydroxychloroquine, in the 14 days prior to inclusion
- Hypokaliemia (<= 3.5 mmol/L), Increase in creatinine (>=120 micromol/Ll, Increase in transaminases at baseline (>=2N)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Arm Title : hydroxychloroquine
|
200 mg BID per day
|
|
Placebo Comparator: Placebo of hydroxychloroquine
|
200 mg BID per day
|
|
Active Comparator: azythromycin
|
250 mg per day
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To assess the impact of hydroxychloroquine and azithromycin on the prevention of SARS-CoV-2 contamination in hospital workers exposed to 40 days of treatment.
Time Frame: 3 months
|
The number of hospital workers with a positive serology or a positive PCR within 40 days of follow-up.
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Reducing clinical episodes due to suspected SARS-2 CoV infection confirmed by PCR
Time Frame: 40 days
|
Clinical signs suggesting SARS-2 CoV infection confirmed by positive endonasal PCR
|
40 days
|
|
Reducing seroconversion for SARS-CoV-2 without any clinical sign
Time Frame: 3 months
|
number of seroconversion by serology between Day 0 and Day 40.
|
3 months
|
|
Evaluation of drug tolerance in the study
Time Frame: 40 days
|
number of cardiological severe adverse events assessed (ECG abnormalities : widening QT, ventricular arythmia, and cardiac arrests), other serious adverse events including hospitalizations, and deaths
|
40 days
|
|
Evaluation on work stopping of hospital workers
Time Frame: 40 days
|
Number of work stoppages over the period
|
40 days
|
|
Observance of treatment measured by plasmatic concentrations of hydroxychloroquine or azythromycine
Time Frame: 40 days
|
Plasmatic concentrations of treatments
|
40 days
|
|
Incidence of cardiologic events
Time Frame: 40 days
|
number of cardiac events, especialy ECG abnormalities (widening QT) due to treatments
|
40 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Jean Ma Treluyer, MD PhD, Assitance publique - Hôpitaux de Paris.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Infections
- Infections
- RNA Virus Infections
- Virus Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Pneumonia, Viral
- Pneumonia
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- COVID-19
- Organic Chemicals
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Macrolides
- Lactones
- Quinolines
- Aminoquinolines
- Erythromycin
- Polyketides
- Chloroquine
- Hydroxychloroquine
- Azithromycin
Other Study ID Numbers
Other Study ID Numbers
- APHP200386
- 2020-001273-73 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.